Japan Lifeline Co., Ltd.TSE: 7575

FYE March 2026 3Q Fact Sheet

Jan 30, 2026 at 7:09 AM UTC · Issued by Japan Lifeline Co., Ltd.

Consolidated Profit and Loss Statement

The fiscal year (FY) ends on March 31 of each year. 'FY20XX' refers to the fiscal year ending March 31, 20XX unless otherwise stated. Amounts less than the indicated unit are rounded down.

Net Sales M

(Net Sales YoY) %

Cost of Goods Sold M Gross Profit M

Gross Profit Margin %

SG&A Expenses M Operating Profit M

(Operating Profit YoY) %

Operating Profit Margin %

FY2018 FY

A 42,298

ï¼‹13.8

15,722

26,576

62.8

15,904

10,671

ï¼‹13.8

25.2

FY2019 FY

A 45,525

ï¼‹7.6

17,703

27,822

61.1

17,295

10,526

(1.4)

23.1

FY2020 FY

A 51,761

ï¼‹13.7

22,570

29,191

56.4

18,756

10,434

(0.9)

20.2

FY2021 FY

A 51,286

(0.9)

22,622

28,664

55.9

18,296

10,367

(0.6)

20.2

FY2022 FY

A 51,469

ï¼‹0.4

22,634

28,835

56.0

18,861

9,973

(3.8)

19.4

FY2023 FY

A 51,750

ï¼‹0.5

21,855

29,895

57.8

19,057

10,837

ï¼‹8.7

20.9

FY2024 FY

A 51,384

(0.7)

20,397

30,986

60.3

20,094

10,892

ï¼‹0.5

21.2

FY2025 FY

A 56,610

ï¼‹10.2

22,419

34,191

60.4

21,864

12,326

ï¼‹13.2

21.8

Q1 A

14,616

ï¼‹4.3

5,846

8,769

60.0

5,497

3,272

ï¼‹2.4

22.4

Q2 A

14,668

ï¼‹5.0

5,880

8,787

59.9

5,439

3,347

ï¼‹9.2

22.8

Q3 A

15,120

ï¼‹2.0

6,164

8,955

59.2

5,750

3,204

(12.1)

21.2

FY2026

YoY %

ï¼‹294 ï¼‹2.0

ï¼‹285 ï¼‹4.9

ï¼‹8 ï¼‹0.1

ï¼‹450 ï¼‹8.5

(441) (12.1)

Q3-YTD A 44,405

ï¼‹3.7

17,892

26,512

59.7

16,687

9,824

(0.8)

22.1

YoY %

ï¼‹1,593 ï¼‹3.7

ï¼‹991 ï¼‹5.9

ï¼‹602 ï¼‹2.3

ï¼‹684 ï¼‹4.3

(82) (0.8)

E*1 29,300

ï¼‹4.7

11,900

17,400

59.4

11,100

6,300

ï¼‹0.6

21.5

H2 E

30,000

ï¼‹4.8

12,000

18,000

60.0

11,400

6,600

ï¼‹8.8

22.0

FY2026 FY

E 59,300

ï¼‹4.8

23,900

35,400

59.7

22,500

12,900

ï¼‹4.7

21.8

YoY %

ï¼‹2,689 ï¼‹4.8

ï¼‹1,480 ï¼‹6.6

ï¼‹1,208 ï¼‹3.5

ï¼‹635 ï¼‹2.9

ï¼‹573 ï¼‹4.7

Non-Operating Income M

Non-Operating Expenses M Ordinary Profit M

Ordinary Profit Margin %

259

200

10,730

25.4

571

289

10,808

23.7

891

900

10,425

20.1

1,031

879

10,519

20.5

316

285

10,005

19.4

293

224

10,905

21.1

390

701

10,581

20.6

336

327

12,335

21.8

3,223

22.1

3,400

23.2

296

2,983

19.7

(98)

ï¼‹253

(793)

(56.7)

ï¼‹585.6

(21.0)

170

387

9,608

21.6

(92)

ï¼‹162

(336)

(35.1)

ï¼‹72.3

(3.4)

100

6,300

21.5

200

100

6,700

22.3

300

200

13,000

21.9

(36)

(127)

ï¼‹664

(10.8)

(39.0)

ï¼‹5.4

Extraordinary Profit M

1 5 3

3 44

100 13 52

ãƒ¼ 0 18

ï¼‹17 ï¼‹1,526.3 18

(10)

(36.2)

ãƒ¼ ãƒ¼ ãƒ¼

(52)

(100.0)

Extraordinary Loss M

Net Profit Before Tax M Tax Expenses M

Net Profit M

Net Profit Margin %

116

10,615

3,137

7,478

17.7

10,801

3,077

7,723

17.0

10,425

2,676

7,748

15.0

5,982

4,540

2,540

2,000

3.9

10,041

2,556

7,484

14.5

1,217

9,789

2,897

6,891

13.3

10,575

3,060

7,515

14.6

362

12,024

2,707

9,317

16.5

3,197

894

2,302

15.8

3,385

913

2,472

16.9

154

2,847

801

2,046

13.5

ï¼‹134

(910)

(320)

(589)

ï¼‹668.9

(24.2)

(28.6)

(22.4)

196

9,430

2,608

6,821

15.4

ï¼‹160

(507)

(257)

(249)

ï¼‹445.0

(5.1)

(9.0)

(3.5)

6,250

1,750

4,500

15.4

6,650

1,800

4,850

16.2

100

12,900

3,550

9,350

15.8

(262)

ï¼‹875

ï¼‹842

ï¼‹32

(72.4)

ï¼‹7.3

ï¼‹31.1

ï¼‹0.3

Basic EPS		98.51	96.05	96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.24	29.17		97.25		64.17	69.13	133.30
Diluted EPS		98.44	95.86	96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.23	29.16		97.24		ãƒ¼	ãƒ¼	ãƒ¼

Proprietary Sales Mix	%	55.4	54.9	50.7	49.9	52.4	54.9	58.8	57.4	55.6	54.7	56.1		55.5		56.9	59.4	58.1
Internatinal Sales Mix	%	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	1.4	1.9	2.4	2.7	2.5		2.5		2.2	2.0	2.1

R&D Expenses (A)	M	1,121	1,431	1,743	1,667	2,159	2,316	2,366	2,851	662	657	898	ï¼‹370	ï¼‹70.1	2,217	ï¼‹562	ï¼‹34.0	1,607	1,591	3,198	ï¼‹347	ï¼‹12.2
Clinical Trials & Regulatory Expenses (B)	M	126	100	80	69	306	19	70	123	33	28	20	(13)	(39.9)	82	(14)	(15.1)	91	82	174	ï¼‹51	ï¼‹41.8
R&D Investments (A)+(B)	M	1,247	1,532	1,823	1,737	2,465	2,335	2,436	2,974	695	685	918	ï¼‹356	ï¼‹63.4	2,300	ï¼‹547	ï¼‹31.3	1,698	1,674	3,373	ï¼‹398	ï¼‹13.4
Capital Expenditure	M	3,630	1,248	2,536	1,382	1,633	976	3,568	1,626	230	225	119	(601)	(83.4)	575	(827)	(59.0)	1,040	1,450	2,490	ï¼‹864	ï¼‹53.1
Depreciation Expenses	M	953	1,176	1,264	1,525	1,611	1,566	1,471	1,779	404	410	417	(37)	(8.3)	1,232	(83)	(6.4)	815	847	1,663	(116)	(6.5)
*1 Disclosed on May 7, 2025

Consolidated Balance Sheet

Amounts less than the indicated unit are rounded down.

	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
	FY A	FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3
	FY A	FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	A	vs. Prev. yr-end	%
Current Assets M	40,821	41,665	44,077	44,522	45,153	47,130	42,871	44,336	41,322	44,824	44,652	ï¼‹315	ï¼‹0.7
Tangible Fixed Assets M	9,914	9,920	11,341	13,111	12,911	12,452	13,434	13,285	13,256	13,145	13,709	ï¼‹423	ï¼‹3.2
Intangible Fixed Assets M	576	558	493	505	1,470	2,414	2,292	1,910	1,808	1,724	1,630	(279)	(14.6)
Investments and Others M	9,668	15,638	19,089	14,822	13,662	12,643	14,910	15,590	14,782	15,581	16,065	ï¼‹475	ï¼‹3.0
Fixed Assets M	20,159	26,117	30,923	28,439	28,044	27,510	30,638	30,786	29,847	30,450	31,405	ï¼‹619	ï¼‹2.0
Total Assets M	60,980	67,783	75,000	72,962	73,197	74,641	73,509	75,123	71,169	75,274	76,058	ï¼‹935	ï¼‹1.2
Current Liabilities M	15,452	14,580	16,093	16,467	14,211	14,381	14,175	14,334	12,034	13,577	12,147	(2,187)	(15.3)
Long-term Liabilities M	4,438	6,709	7,500	5,190	4,418	4,063	1,231	874	789	719	715	(159)	(18.2)
Total Liabilities M	19,890	21,289	23,594	21,657	18,629	18,445	15,406	15,208	12,823	14,297	12,862	(2,346)	(15.4)
Shareholder's Equity M	41,088	46,496	51,618	51,267	54,362	56,265	57,516	58,675	57,289	59,833	61,880	ï¼‹3,204	ï¼‹5.5
Accumulated other comprehensiv M	(11)	(16)	(211)	37	205	(69)	585	1,239	1,056	1,131	1,286	ï¼‹46	ï¼‹3.8
Share Warrant M	13	13	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	12	29	ï¼‹29	ãƒ¼
Net Assets M	41,090	46,493	51,406	51,304	54,567	56,195	58,102	59,914	58,346	60,977	63,196	ï¼‹3,281	ï¼‹5.5
Total Liabilities and Net Assets M	60,980	67,783	75,000	72,962	73,197	74,641	73,509	75,123	71,169	75,274	76,058	ï¼‹935	ï¼‹1.2

Cash and Deposits	M	6,732	8,018	9,555	13,708	16,058	18,357	12,669	11,014	7,467	9,630	8,644	(2,370)	(21.5)
Accounts Receivables	M	12,331	12,178	13,762	13,145	12,437	13,223	13,283	13,830	14,170	14,435	15,115	ï¼‹1,285	ï¼‹9.3
Inventory	M	13,579	17,071	18,187	15,987	14,850	13,142	15,154	17,961	18,188	19,146	19,287	ï¼‹1,325	ï¼‹7.4
Accounts Payables	M	2,278	3,087	4,081	2,872	3,287	3,429	4,254	4,358	3,782	4,455	3,916	(442)	(10.1)
Retained Earnings	M	25,091	30,499	35,912	35,352	38,890	42,741	47,291	53,455	52,035	54,507	56,554	ï¼‹3,098	ï¼‹5.8
Interest-Bearing Debt	M	9,396	9,987	11,538	10,396	8,352	6,883	4,634	3,973	3,864	3,812	3,458	(515)	(13.0)
Net Debt	M	2,663	1,968	1,983	(3,311)	(7,705)	(11,473)	(8,034)	(7,041)	(3,602)	(5,818)	(5,185)	ï¼‹1,855	(26.3)
Invested Capital*1	M	50,484	56,484	63,156	61,663	62,714	63,148	62,151	62,648	61,154	63,645	65,338	ï¼‹2,689	ï¼‹4.3
Working Capital*2	M	23,632	26,161	27,868	26,260	24,000	22,937	24,183	27,433	28,577	29,125	30,486	ï¼‹3,053	ï¼‹11.1

*1 A sum of interest-bearing debt and shareholder's equity

*2 Accounts receivables + Inventory - Accounts payables

Consolidated Cash Flows

Amounts less than the indicated unit are rounded down.

	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
	FY A	FY A	FY A	FY A	FY A	FY A	FY A	FY A
Operating Cash Flows M	4,450	7,037	7,096	11,432	10,246	11,201	6,918	9,113
Investing Cash Flows M	(9,161)	(9,964)	(4,419)	(3,731)	(1,131)	(2,461)	(4,056)	(1,801)
Financing Cash Flows M	11,294	(1,783)	(1,136)	(3,720)	(6,804)	(6,476)	(8,553)	(9,040)
Others M	1	(3)	(4)	172	38	35	4	74
Net change in cash and cash equiva M	6,584	(4,713)	1,536	4,153	2,349	2,298	(5,688)	(1,654)
Cash and cash equivalents at end o M	12,732	8,018	9,555	13,708	16,058	18,357	12,669	11,014

Financial Indicators

Amounts less than the indicated unit are rounded down.

		FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026				FY2026
		FY A	FY A	FY A	FY A	FY A	FY A	FY A	FY A	Q1 A	Q2 A	Q3 A	Q3-YTD A	H1 E	H2 E	FY E
No. of Issued Shares at YR-End (incl. treasury shares)	K	90,419	90,419	85,419	85,419	85,419	82,919	75,758	75,758	71,300	71,300	71,300	71,300	ãƒ¼	ãƒ¼	ãƒ¼
No. of Treasury Shares at YR-End*1	K	10,005	10,005	5,165	5,050	5,500	4,999	829	5,661	1,185	1,143	1,144	1,144	ãƒ¼	ãƒ¼	ãƒ¼
Ave No. of O/S Shares at YR-End (excl. treasury shares)*2	K	75,914	80,414	80,251	80,322	80,367	78,116	76,122	70,890	70,102	70,156	70,155	70,138	ãƒ¼	ãƒ¼	ãƒ¼
Basic EPS*3		98.51	96.05	96.55	24.91	93.13	88.22	98.73	131.43	32.85	35.24	29.17	97.25	64.17 ãƒ¼ãƒ¼ãƒ¼ãƒ¼ãƒ¼ãƒ¼ãƒ¼ ãƒ¼	69.13 ãƒ¼ãƒ¼ãƒ¼ãƒ¼ãƒ¼ãƒ¼ãƒ¼ ãƒ¼	133.30
BPS		510.81	578.01	640.54	638.36	682.79	721.20	775.43	854.74	832.15	868.99	900.37	900.37			928.71
DPS		28.75	29.00	29.00	49.00	38.00	38.00	42.00	53.00	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼			54.00
DOE %		7.3	5.3	4.8	7.7	5.8	5.4	5.6	6.5	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼			6.1
Payout Ratio %		29.2	30.2	30.0	196.7	40.8	43.1	42.5	40.3	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼			40.5
ROE %		24.2	17.6	15.8	3.9	14.1	12.4	13.2	15.8	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼			15.0
ROA %		21.2	16.8	14.6	14.2	13.7	14.8	14.3	16.6	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼			16.8
ROIC*4 %		14.7	13.7	12.1	11.5	11.1	11.9	12.1	13.7	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼			13.8
Capital-to-Asset Ratio %		67.4	68.6	68.5	70.3	74.5	75.3	79.0	79.8	82.0	81.0	83.0	83.0			81.6
Receivabes Turnover Period	Day	101	98	91	96	91	90	94	89	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	86
Inventory Turnover Period	Day	277	316	285	276	249	234	253	283	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	280
Payables Turnover Period	Day	48	55	58	56	50	56	69	70	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	67
Cash Conversion Cycle	Day	330	359	319	315	290	268	279	302	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	300
Number of Employees (Consolidated) Person		906	932	1,074	1,167	1,205	1,166	1,216	1,250	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼	ãƒ¼

*1 Company shares held by the BIP Trust for directors and Company shares held by the Trust for the Trust-type Employee Shareholding Incentive Plan (E-Ship) are included in treasury shares. (E-Ship terminated on July 29, 2021)

*2 Values for each Q are for the accounting period

*3 EPS after taking into account the stock split. A 1:2 stock split was carried out in Jan. 2018. In light of this, EPS for FY2018 is calculated assuming that the stock split took place at the beginning of the fiscal year

*4 Denominator profit is operating profit after tax. After-tax operating profit = operating profit *(1 - effective tax rate (30.62%))

Sales by Product
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Amounts less than the indicated unit are rounded down.
FY2026
Pacemaker*6 M
ICD*6 M
Others M
Cardiac Rhythm Management TTL M (CRM YoY) %
EP Catheter M
ABL Catheter M
Others M
EP/Ablation TTL M
(EP/ABL YoY) %
Artificial Heart Valve M
Vascular Graft M
Blood Purification*1 M
Others*3*5 M
Cardiovascular*ï¼”TTL M (CV YoY) %
FY A
6,463
584
200
7,247
ï¼‹9.5
15,354
1,161
3,848
20,364
ï¼‹16.2
1,742
8,482
1,131
106
11,464
ï¼‹26.0
FY A
5,169
496
196
5,862
(19.1)
17,028
1,369
4,662
23,060
ï¼‹13.2
1,448
9,133
1,070
77
11,730
ï¼‹2.3
FY A
5,682
5,960
223
11,866
ï¼‹102.4
17,915
1,421
5,358
24,696
ï¼‹7.1
259
8,879
994
32
10,166
(13.3)
FY A
5,996
7,001
250
13,248
ï¼‹11.7
17,314
1,047
5,501
23,863
(3.4)
ãƒ¼
9,039
ãƒ¼
929
9,969
(1.9)
FY A
5,899
6,747
330
12,977
(2.0)
18,412
1,232
5,455
25,099
ï¼‹5.2
ãƒ¼
9,368
ãƒ¼
748
10,117
ï¼‹1.5
FY A
4,979
7,049
374
12,403
(4.4)
19,654
1,011
5,626
26,292
ï¼‹4.8
ãƒ¼
10,353
ãƒ¼
423
10,776
ï¼‹6.5
FY A
5,241
7,857
402
13,501
ï¼‹8.9
21,211
840
2,197
24,249
(7.8)
ãƒ¼
10,956
ãƒ¼
449
11,406
ï¼‹5.9
FY A
4,506
8,296
464
13,267
(1.7)
22,543
647
4,654
27,845
ï¼‹14.8
ãƒ¼
11,688
ãƒ¼
517
12,206
ï¼‹7.0
Q1 A
1,049
2,136
199
3,386
(2.4)
5,653
87
1,535
7,276
ï¼‹2.5
ãƒ¼
2,848
ãƒ¼
161
3,010
ï¼‹8.1
Q2 A 960
2,094
225
3,280
ï¼‹0.8
5,708
73
1,647
7,430
ï¼‹5.8
ãƒ¼
2,685
ãƒ¼
240
2,926
ï¼‹1.9
Q3 A 972
2,145
210
3,329
(1.9)
5,493
83
1,620
7,197
(0.4)
ãƒ¼
3,217
ãƒ¼
186
3,404
ï¼‹1.9
YoY (142)
(25)
ï¼‹103
(64)
(272)
(69)
ï¼‹310
(31)
ãƒ¼
ï¼‹13
ãƒ¼
ï¼‹50
ï¼‹64
% (12.8)
(1.2)
ï¼‹96.2
(1.9)
(4.7)
(45.3)
ï¼‹23.7
(0.4)
ãƒ¼
ï¼‹0.4
ãƒ¼
ï¼‹37.3
ï¼‹1.9
Q3-YTD A 2,982
6,376
636
9,995
(1.2)
16,856
245
4,803
21,904
ï¼‹2.6
ãƒ¼
8,751
ãƒ¼
589
9,341
ï¼‹3.8
YoY (612)
ï¼‹191
ï¼‹297
(123)
(593)
(300)
ï¼‹1,445
ï¼‹552
ãƒ¼
ï¼‹140
ãƒ¼
ï¼‹204
ï¼‹345
% (17.0)
ï¼‹3.1
ï¼‹87.9
(1.2)
(3.4)
(55.0)
ï¼‹43.0
ï¼‹2.6
ãƒ¼
ï¼‹1.6
ãƒ¼
ï¼‹53.0
ï¼‹3.8
H1 E
2,160
4,320
400
6,880
ï¼‹2.3
11,680
215
2,705
14,600
ï¼‹3.4
ãƒ¼
5,590
ãƒ¼
280
5,870
ï¼‹3.8
H2 E
1,980
3,890
480
6,350
(2.9)
11,730
195
2,620
14,545
ï¼‹6.0
ãƒ¼
6,540
ãƒ¼
240
6,780
ï¼‹3.5
FY E
4,140
8,210
880
13,230
(0.3)
23,410
410
5,325
29,145
ï¼‹4.7
ãƒ¼
12,130
ãƒ¼
520
12,650
ï¼‹3.6
YoY (366)
(86)
ï¼‹415
(37)
ï¼‹866
(237)
ï¼‹670
ï¼‹1,299
ãƒ¼
ï¼‹441
ãƒ¼
ï¼‹2
ï¼‹443
% (8.1)
(1.0)
ï¼‹89.6
(0.3)
ï¼‹3.8
(36.7)
ï¼‹14.4
ï¼‹4.7
ãƒ¼
ï¼‹3.8
ãƒ¼
ï¼‹0.5
ï¼‹3.6
Neurovascular*5*7 M
Neurovascular TTL M (NV YoY) %
ãƒ¼ ãƒ¼ ãƒ¼
ãƒ¼ ãƒ¼ ãƒ¼
ãƒ¼ ãƒ¼ ãƒ¼
ãƒ¼ 12
ãƒ¼ 12
ãƒ¼ ãƒ¼
230
230
ï¼‹1,753.6
912
912
ï¼‹296.7
1,842
1,842
ï¼‹101.9
562
562
ï¼‹61.9
624
624
ï¼‹38.0
726
726
ï¼‹47.7
ï¼‹234 ï¼‹47.7
ï¼‹234 ï¼‹47.7
1,913
1,913
ï¼‹48.1
ï¼‹621 ï¼‹48.1
ï¼‹621 ï¼‹48.1
1,045
1,045
ï¼‹30.6
1,215
1,215
ï¼‹16.6
2,260
2,260
ï¼‹22.7
ï¼‹417 ï¼‹22.7
ï¼‹417 ï¼‹22.7
Gastrointestinal M
28 107
132
247
453
654
925
1,345
352
394
463
ï¼‹112
ï¼‹32.1
1,210
ï¼‹262
ï¼‹27.6
840
1,055
1,895
ï¼‹549
ï¼‹40.9
Others*3 M
Gastrointestinal*2*3TTL M (GI YoY) %
Consolidated Net Sales M (Consolidated Net Sales YoY) %
*1 Included in "Others" since FY2021
3,193
3,221
ï¼‹15.7
42,298
ï¼‹13.8
4,765
4,872
ï¼‹51.2
45,525
ï¼‹7.6
4,900
5,032
ï¼‹3.3
51,761
ï¼‹13.7
3,957
4,204
(16.5)
51,286
(0.9)
2,808
3,261
(22.4)
51,469
ï¼‹0.4
1,394
2,048
(37.2)
51,750
ï¼‹0.5
388
1,314
(35.8)
51,384
(0.7)
103
1,448
ï¼‹10.2
56,610
ï¼‹10.2
28
380
ï¼‹23.9
14,616
ï¼‹4.3
12
406
ï¼‹9.0
14,668
ï¼‹5.0
ãƒ¼
463
ï¼‹24.6
15,120
ï¼‹2.0
(20) (100.0)
ï¼‹91 ï¼‹24.6
ï¼‹294 ï¼‹2.0
40
1,250
ï¼‹18.9
44,405
ï¼‹3.7
(63) (61.2)
ï¼‹198 ï¼‹18.9
ï¼‹1,593 ï¼‹3.7
65
905
ï¼‹33.0
29,300
ï¼‹4.7
55
1,110
ï¼‹44.4
30,000
ï¼‹4.8
120
2,015
ï¼‹39.1
59,300
ï¼‹4.8
ï¼‹16 ï¼‹15.7
ï¼‹566 ï¼‹39.1
ï¼‹2,689 ï¼‹4.8
*2 Renamed from "Transvascular Intervention" to "Gastrointestinal/PI" since FY2023
*3 Renamed from "Gastrointestinal/PI" to "Gastrointestinal" since FY2024 as PI businesses are downsized. Its subcategory "PI-related" is renamed to "Others". Sales of structural heart disease-related is moved to "Cardiovascular, Others" (Reclassifications)
*4 Renamed from "Cardiovascular Surgery" to "Cardiovascular" since FY2024
*5 Sales of neurovascular-related is moved from "Cardiovascular, Others" to an new independent category of "Cardiovascular, Neurovascular" (Reclassifications)
*6 Sales of left ventricular pacing lead is moved from "ICD" to "Pacemaker" since FY2024 (Reclassifications)
*7 Sales of neurovascular in the sub-groupe of CV is moved to a new independent main groupe (Reclassifications)
*8 Reclassifications regarding *3, *5, *6, and *7 are retroactively applied to FY2021 and onward.
Products Included in Product Categories (As of Dec. 2025)

*Listed in descending order of composition ratio. *Red text indicates items defined as "Core Products." *Underlined text indicates proprietary products.

Cardiac Rhythm Management
Pacemaker	Pacemaker, CRT-P (Cardiac Resynchronization Therapy Pacemaker)
ICD	S-ICD (Subcutaneous Implantable Cardioverter Defibrillator), T-ICD (Transvenous Implantable Cardioverter Defibrillator),
	CRT-D (Cardiac Resynchronization Therapy Defibrillator)
Others	AED (Automated External Defibrillator), Lead management device
EP/Ablation	Intracardiac Defibrillation Catheter, Electrophisiology Catheter, Esophageal Temperature Monitoring Catheter
EP Catheter
ABL Catheter	Ablation Catheter, Endoscopic Laser Ablation Catheter
Others	Hemostatic Device for Femoral Vein, Steerable Sheath, Console, accessory, service fees and others
Cardiovascular	Abdominal Stent Graft (for EVAR), Frozen Elephant Trunkã€Vascular Graft
Vascular Graft
Others	Atrial Septum Defect Closure Device, Pressure-sensor-equipped Guidewire for TAVI, Delicery Catheter System (for regenerative medicine products)
Neurovascular	Embolic Coil, Aspiration Catheter, Stent Retriever, Distal Access Catheter, Micro Catheter
Neurovascuar
Gastrointestinal	Bile-duct Tube Stent, Liver Cancer Ablation Needle, Colonic Stent, ERCP Guidewire, Gastro-Duodenal Stent, Bile-duct Dilation Balloon, Constrast Catheter,
Gastrointestinal
	Double-Lumen Dilator
Others	Coronary Intervention-related (Terminated Business)